carfilzomib + ibrutinib

Carfilzomib + ibrutinib is an investigational combination therapy studied primarily for relapsed or refractory multiple myeloma. Carfilzomib is a selective, irreversible proteasome inhibitor that binds to the N-terminal threonine-containing active sites of the 20S proteasome, leading to inhibition of protein degradation and induction of apoptosis in cancer cells[8]. Ibrutinib is a small molecule inhibitor of Bruton’s tyrosine kinase (BTK), which blocks B-cell receptor signaling by covalently binding to BTK at Cys481, thereby inhibiting downstream survival pathways in malignant B-cells[1][3]. The combination has shown encouraging response rates and manageable safety profiles in early-phase clinical trials for patients with advanced multiple myeloma who have failed prior therapies[2][4].